# Regenerative Medicine for COVID-19 and Flu-Elicited ARDS Using Lomecel-B (RECOVER)

> **NCT04629105** · PHASE1 · UNKNOWN · sponsor: **Longeveron Inc.** · enrollment: 70 (estimated)

## Conditions studied

- ARDS, Human
- Covid19

## Interventions

- **BIOLOGICAL:** Longeveron Mesenchymal Stem Cells (LMSCs)
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04629105
- **Lead sponsor:** Longeveron Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-07-24
- **Primary completion:** 2024-06
- **Final completion:** 2025-07
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2024-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04629105

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04629105, "Regenerative Medicine for COVID-19 and Flu-Elicited ARDS Using Lomecel-B (RECOVER)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04629105. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*